Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

Sandoz on Monday signed a development and commercialization contract with Samsung Bioepis for SB17, the latter’s biosimilar to Johnson & Johnson’s Stelara (ustekinumab).